Company: PTHS
Filing Date: 2025-09-29
Form Type: 424B3
Source: 0001753926-25-001561
Chunk: 59

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-09-29
Form: 424B3
Chunk 59
---
 controls or any significant additional taxes or fees that may be imposed on the biopharmaceutical industry as part of deficit reduction efforts could reduce cash flows and adversely affect our business, financial condition or results of operations.

<div align='center'>33

THE OFFERING</div>

| Company                                                      
 Common Stock offered by the Selling Stockholders:            | This                                                                                                                          
 prospectus relates to 8,137,868 shares of Company Common Stock that may be sold from time to time by the Selling Stockholders 
 named in this prospectus.                                                                                                     |
| Company                                                      
 Common Stock outstanding at commencement of the offering(1): | 3,067,974                                                                                                                     
 shares of Company Common Stock.                                                                                               |
| Use                                                          
 of proceeds:                                                 | We                                                                                                                            
 will not receive any proceeds from the sales of outstanding shares of Common Stock by the Selling Stockholders.               |
| Risk                                                         
 factors:                                                     | Investing                                                                                                                     
 in our Company Common Stock involves a high degree of risk. See “Risk factors” beginning on page                              
 7  of this     prospectus for a discussion of some of the factors you should carefully consider before                        
 deciding to invest in our Company     Common Stock.                                                                           |
| Trading                                                      
 market and symbol:                                           | Our                                                                                                                           
 Common Stock is currently listed on the NYSE American LLC under the symbol “PTHS”.                                            |

(1) The
number of shares of Common Stock outstanding at the commencement of the offering is based on 3,067,974 shares of Company Common
Stock outstanding as of the date of this prospectus, and excludes:

| ● | 2,628,900                                                                                                                      
 shares of Common Stock issuable upon conversion of 26,289 shares of Series A Preferred Stock which have not yet been converted 
 into shares of our Common Stock;                                                                                               |

| ● | 1,557,074 shares                                                                                                            
 of Common Stock issuable upon the exercise of outstanding options granted under our amended and equity incentive plan, with 
 a weighted average exercise price of $16.01;                                                                                |

| ● | 515,520 shares of                                                                                            
 Common Stock underlying restricted stock units granted under our amended and restated equity incentive plan; |

| ● | 5,500 shares of                                                                                                                 
 Common Stock issuable upon the exercise of outstanding warrants to purchase shares of our Common Stock granted under our equity 
 incentive plan, with a weighted average exercise price of $75.00; and                                                           |

| ● | 327,406 shares